{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:19:07Z","timestamp":1783523947546,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.det.2024.02.011","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T21:15:34Z","timestamp":1712783734000},"page":"471-480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Paradoxical Psoriasis"],"prefix":"10.1016","volume":"42","author":[{"given":"Mariam","family":"Abdelghaffar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sita","family":"Kottilil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Damsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.det.2024.02.011_bib1","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ad.2013.05.007","article-title":"Reacciones Psoriasiformes parad\u00f3jicas Durante El tratamiento con terapia anti-factor de necrosis tumoral. Manejo Cl\u00ednico","volume":"105","author":"Navarro","year":"2014","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"issue":"2","key":"10.1016\/j.det.2024.02.011_bib2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/2475530318810851","article-title":"TNF inhibitor-induced psoriasis: Proposed algorithm for treatment and management","volume":"4","author":"Li","year":"2018","journal-title":"J\u00a0Psoriasis Psoriatic Arthritis"},{"issue":"5 suppl 1","key":"10.1016\/j.det.2024.02.011_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1590\/abd1806-4841.20164456","article-title":"Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis","volume":"91","author":"Vasconcellos","year":"2016","journal-title":"An Bras Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.011_bib4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1159\/000530608","article-title":"Dupilumab-associated psoriasis and psoriasiform manifestations: A scoping review","volume":"239","author":"Su","year":"2023","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2024.02.011_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: Classical vs. paradoxical. The Yin-yang of TNF and type I interferon","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.det.2024.02.011_bib6","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.011_bib7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience","volume":"76","author":"Brown","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.011_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases","volume":"20","author":"Ko","year":"2009","journal-title":"J\u00a0Dermatol Treat"},{"issue":"3","key":"10.1016\/j.det.2024.02.011_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.det.2024.02.011_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: An analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.det.2024.02.011_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13142","article-title":"Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series","volume":"32","author":"Napolitano","year":"2019","journal-title":"Dermatol Ther"},{"issue":"10","key":"10.1016\/j.det.2024.02.011_bib12","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.jid.2022.03.013","article-title":"T\u00a0helper 2 il-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17\u2012type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases","volume":"142","author":"Bridgewood","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.011_bib13","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2258240","article-title":"Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis","volume":"34","author":"Balakirski","year":"2023","journal-title":"J\u00a0Dermatol Treat"},{"issue":"7","key":"10.1016\/j.det.2024.02.011_bib14","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.det.2024.02.011_bib15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/tpj.2015.53","article-title":"Paradoxical psoriasiform reactions to anti-tnf\u03b1 drugs are associated with genetic polymorphisms in patients with psoriasis","volume":"16","author":"Cabaleiro","year":"2015","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"10.1016\/j.det.2024.02.011_bib16","first-page":"16","article-title":"Palmoplantar pustulosis with fulminant dystrophic 20-nail psoriasis in a patient receiving adalimumab therapy","volume":"12","author":"Mishra","year":"2013","journal-title":"J\u00a0Drugs Dermatol JDD"},{"key":"10.1016\/j.det.2024.02.011_bib17","first-page":"1","article-title":"Adalimumab-induced paradoxical psoriasis treated with biologics targeting the IL-17\/IL-23 axis in patients with Hidradenitis Suppurativa","author":"Tsiogka","year":"2023","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.det.2024.02.011_bib18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1525-1470.2011.01521.x","article-title":"Five cases of anti-tumor necrosis factor alpha\u2013induced psoriasis presenting with severe scalp involvement in children","volume":"29","author":"Perman","year":"2011","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.011_bib19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/pde.13859","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis in juvenile idiopathic arthritis patients","volume":"36","author":"Groth","year":"2019","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.011_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40257-022-00749-1","article-title":"Development of cutaneous T-cell lymphoma following biologic treatment: A systematic review","volume":"24","author":"Schaefer","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.02.011_bib21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/ijd.16388","article-title":"Cutaneous t-cell lymphoma following dupilumab use: A systematic review","volume":"62","author":"Park","year":"2022","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.011_bib22","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jaad.2017.12.068","article-title":"Progression of undiagnosed cutaneous lymphoma after anti\u2013tumor necrosis factor-alpha therapy","volume":"78","author":"Martinez-Escala","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.011_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2020.01.006","article-title":"Histologic comparison of tumor necrosis factor-\u03b1 inhibitor\u2013induced psoriasis and psoriasis vulgaris","volume":"83","author":"Hu","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.011_bib24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/cup.12932","article-title":"tnf-inhibitor associated psoriatic alopecia: Diagnostic utility of sebaceous lobule atrophy","volume":"44","author":"Afanasiev","year":"2017","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.det.2024.02.011_bib25","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.7831","article-title":"Clinical psoriasiform dermatitis following dupilumab use for autoeczematization secondary to chronic stasis dermatitis","author":"Schrom","year":"2020","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.det.2024.02.011_bib26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bjd.20064","article-title":"Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized byde novointerleukin-17a expression: A case report","volume":"185","author":"Mirza","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.011_bib27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.annder.2021.02.003","article-title":"Dupilumab-induced psoriasis and alopecia areata: Case report and review of the literature","volume":"148","author":"Beaziz","year":"2021","journal-title":"Ann Dermatol V\u00e9n\u00e9r\u00e9ol"},{"issue":"5","key":"10.1016\/j.det.2024.02.011_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/ar3150","article-title":"Type I IFN and TNF\u0391 cross-regulation in immune-mediated inflammatory disease: Basic concepts and clinical relevance","volume":"12","author":"Cantaert","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.det.2024.02.011_bib29","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-\u03b1 in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.det.2024.02.011_bib30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/art.1780250407","article-title":"Serum interferon levels in patients with systemic lupus erythematosus","volume":"25","author":"Ytterberg","year":"1982","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.det.2024.02.011_bib31","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1191\/096120300674499064","article-title":"Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies","volume":"9","author":"Bengtsson","year":"2000","journal-title":"Lupus"},{"issue":"5546","key":"10.1016\/j.det.2024.02.011_bib32","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1126\/science.1064890","article-title":"Induction of dendritic cell differentiation by IFN-\u03b1 in systemic lupus erythematosus","volume":"294","author":"Blanco","year":"2001","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.det.2024.02.011_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.det.2024.02.011_bib34","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1365-2133.2009.09329.x","article-title":"Cytokine imbalance with increased production of interferon-\u03b1 in psoriasiform eruptions associated with antitumour necrosis factor-\u03b1 treatments","volume":"161","author":"Seneschal","year":"2009","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.011_bib35","first-page":"55","article-title":"Paradoxical psoriasis induced by tnf-\u03b1 blockade shows immunological features typical of the early phase of psoriasis development","volume":"6","author":"Fania","year":"2019","journal-title":"J\u00a0Pathol: Clin Res"},{"key":"10.1016\/j.det.2024.02.011_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","article-title":"Atopic dermatitis and psoriasis: Two different immune diseases or one spectrum?","volume":"48","author":"Guttman-Yassky","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.det.2024.02.011_bib37","article-title":"Genomic profiling of the overlap phenotype between psoriasis and atopic dermatitis","author":"Kim","year":"2023","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.011_bib38","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaad.2022.12.052","article-title":"Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis","volume":"88","author":"Singh","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.011_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.det.2024.02.011_bib40","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.1416922112","article-title":"Il-4 abrogates T h 17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells","volume":"112","author":"Guenova","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.det.2024.02.011_bib41","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/rheumatology\/keaa568","article-title":"Regulation of entheseal IL-23 expression by il-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy","volume":"60","author":"Bridgewood","year":"2020","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.det.2024.02.011_bib42","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4049\/jimmunol.160.7.3513","article-title":"IL-17 stimulates the production and expression of proinflammatory cytokines, IL-\u03b2 and TNF-\u03b1, by human macrophages","volume":"160","author":"Jovanovic","year":"1998","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"10.1016\/j.det.2024.02.011_bib43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bjd.19459","article-title":"Increased expression of interleukin-23a in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment","volume":"184","author":"Napolitano","year":"2020","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.011_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2022.10.015","article-title":"IL-4\/IL-13 inhibitors for atopic dermatitis induce psoriatic rash transcriptionally close to pustular psoriasis","volume":"143","author":"Grolleau","year":"2023","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.011_bib45","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaad.2021.05.013","article-title":"Development of psoriasis during treatment with dupilumab: A systematic review","volume":"86","author":"Brumfiel","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.02.011_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.19351","article-title":"Successful treatment with tralokinumab in patients with atopic dermatitis and dupilumab-induced psoriasis","author":"Quattrini","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2024.02.011_bib47","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.det.2023.02.003","article-title":"Diagnosing Atopic Dermatitis in Skin of Color","volume":"41","author":"Adawi","year":"2023","journal-title":"Dermatol Clin"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T01:39:01Z","timestamp":1731721141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0733863524000238"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.02.011","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paradoxical Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}